Harry Lively, MD
Cardiovascular Disease · Visalia, CANPI 1922154863
Payments from drug & device makers
Across 99 payments — averaging $82.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Siemens Medical Solutions USA, Inc.$2K
- Boston Scientific$2K
- Novartis$519
- Medtronic$437
- Abiomed$433
- Artivion, Inc.$402
- plus $3K from 22 others
What the payments were for
- Travel & lodging$2,45330%
- Food & beverage$5,67670%
- Gifts$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Siemens Medical Solutions USA, Inc. | 15 | $2,119 |
| Boston Scientific | 19 | $1,626 |
| Novartis | 11 | $519 |
| Medtronic | 7 | $437 |
| Abiomed | 6 | $433 |
| Artivion, Inc. | 1 | $402 |
| Amgen | 7 | $389 |
| Lantheus Medical Imaging, Inc. | 4 | $341 |
| Cathworks, Inc. | 1 | $220 |
| Abbott | 3 | $212 |
| Cvrx, Inc. | 3 | $207 |
| Novo Nordisk | 3 | $153 |
| Bard Peripheral Vascular, Inc. | 1 | $150 |
| Shockwave Medical, Inc | 1 | $142 |
| Edwards Lifesciences | 2 | $138 |
| Johnson & Johnson | 2 | $129 |
| Actelion Pharmaceuticals US, Inc. | 1 | $121 |
| Teva Pharmaceuticals USA, Inc. | 1 | $100 |
| Bracco Diagnostics Inc. | 1 | $89 |
| Chiesi USA, Inc. | 2 | $41 |
| Inari Medical, Inc. | 1 | $40 |
| Pfizer | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Merck | 1 | $19 |
| AstraZeneca | 1 | $19 |
| Lilly USA, LLC | 1 | $16 |
| Masimo Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACUSON Origin Diagnostic Ultrasound System$1,846
- LUX-Dx Insertable Cardiac Monitor$675
- On-X$402
- Definity$322
- Repatha$250
- ENTRESTO$235
- FFRangio$220
- VENOVO$150
- AVVIGO Guidance System$147
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$142
- VIGILANT X4 CRT-D$131
- Wegovy$125
- myLUX Patient Kit with mobile device$124
- Optis Coronary Imaging System$122
- UPTRAVI$121
- OPSUMIT$121
- AURORA EV-ICD MRI SURESCAN$118
- Impella$111
- SQ RX PULSE GENERATOR$105
- XARELTO$101
How this compares
$8,151 in reported general payments places this provider in the 70th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 12 | $267,987 |
| EliquisApixaban | 123 | $150,255 |
| EntrestoSacubitril/Valsartan | 94 | $107,787 |
| FarxigaDapagliflozin Propanediol | 87 | $106,875 |
| JardianceEmpagliflozin | 48 | $61,140 |
| Repatha SureclickEvolocumab | 57 | $49,919 |
| OzempicSemaglutide | 35 | $35,966 |
| XareltoRivaroxaban | 22 | $27,546 |
| Praluent PenAlirocumab | 12 | $7,683 |
| Repatha SyringeEvolocumab | 12 | $7,390 |
| VascepaIcosapent Ethyl | 12 | $6,673 |
| Rosuvastatin Calcium | 240 | $3,727 |
| Ezetimibe | 131 | $3,141 |
| Metoprolol Succinate | 136 | $2,278 |
| Valsartan | 63 | $2,011 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $29 | $418,243135 claims |
| NovartisEntresto | $519 | $107,78794 claims |
| AstraZenecaFarxiga | $19 | $106,87587 claims |
| Novo NordiskOzempic | $153 | $35,96635 claims |
| Johnson & JohnsonXarelto | $129 | $27,54622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Visalia
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
- Yu-Ping WangStanford$3.8M
- Yogesh PaliwalPomona$3.3M
- Farhad RafiiWest Hills$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.